Cell News and Research

RSS

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer-related products, today announced that data from several clinical trials of nimotuzumab are scheduled be reported at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

27 Sep 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden.

27 Sep 2011

Viewing computer images causes long-term changes in nerve cell connections

Viewing two-dimensional images of the environment, as they occur in computer games, leads to sustained changes in the strength of nerve cell connections in the brain.

27 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

A research group led by Freiburg pharmacologist Prof. Dr. Klaus Aktories and their American colleagues have discovered the cell receptor for the toxin CDT of the bacterium Clostridium difficile.

27 Sep 2011

Smaller and faster clinical drug trials could improve gains in cancer survival

With the advent of personalised medicine, gains in cancer survival over the long term could be improved by running smaller, faster trials with less stringent evidence criteria, a researcher told the 2011 European Multidisciplinary Cancer Congress.

26 Sep 2011

Scientists identify a way that chemotherapy causes platelet numbers to drop

Scientists at the Walter and Eliza Hall Institute have identified a way that chemotherapy causes platelet numbers to drop, answering in the process a decade-old question about the formation of platelets, tiny cells that allow blood to clot.

26 Sep 2011

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced long-term results of the Phase 1 study of its investigational pan-BCR-ABL inhibitor, ponatinib, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia.

26 Sep 2011

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has achieved the target enrollment of the minimum of 100 evaluable relapsed or refractory peripheral T-cell lymphoma (PTCL) patients in the BELIEF registration trial.

26 Sep 2011

InterMune reports new data from Esbriet clinical trial on IPF

InterMune, Inc. today reported that new data was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet(pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF), a devastating lung disease.

26 Sep 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Scientists reveal link between lipid cell dysfunction and metabolic diseases

By measuring the radioactive isotope carbon-14, scientists at Karolinska Institutet have revealed an association between lipid cell dysfunction and diseases such as obesity, diabetes and blood lipid disorders.

26 Sep 2011

Gold nanowires in engineered cardiac patches could help heart attack patients

A team of physicians, engineers and materials scientists at Children's Hospital Boston and the Massachusetts Institute of Technology have used nanotechnology and tiny gold wires to engineer cardiac patches, with cells all beating in time, that could someday help heart attack patients.

26 Sep 2011

Percutaneous hepatic perfusion extends survival time for melanoma patients

Melanoma of the eye frequently spreads to the liver and, once this has happened, there is no effective treatment and patients die within an average of two to four months. Only about one in ten patients live for a year. Now, final results from a phase III study have demonstrated that a new treatment significantly extends the time patients can live without the disease progressing.

26 Sep 2011

City cyclists inhale more black carbon than pedestrians

People who cycle through London and other major cities have higher levels of black carbon in their airway cells, experts from the UK have shown.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Researchers devise protein 'switch' that instructs cancer cells to produce their own medication

Johns Hopkins researchers have devised a protein "switch" that instructs cancer cells to produce their own anti-cancer medication.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Scientists find a way to rapidly produce pure populations of oligodendrocyte progenitor cells

Scientists at Case Western Reserve University School of Medicine found a way to rapidly produce pure populations of cells that grow into the protective myelin coating on nerves in mice. Their process opens a door to research and potential treatments for multiple sclerosis, cerebral palsy and other demyelinating diseases afflicting millions of people worldwide.

26 Sep 2011

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Patrys Limited has announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

26 Sep 2011

Cell News and Research

Data from YM BioSciences' nimotuzumab clinical trials to be reported at ECCO-ESMO 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Viewing computer images causes long-term changes in nerve cell connections

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

Smaller and faster clinical drug trials could improve gains in cancer survival

Scientists identify a way that chemotherapy causes platelet numbers to drop

Long-term results from ARIAD's ponatinib Phase 1 study on CML and Ph+ ALL

Enrollment complete in Spectrum Pharmaceuticals' belinostat pivotal trial for PTCL

InterMune reports new data from Esbriet clinical trial on IPF

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Scientists reveal link between lipid cell dysfunction and metabolic diseases

Gold nanowires in engineered cardiac patches could help heart attack patients

Percutaneous hepatic perfusion extends survival time for melanoma patients

City cyclists inhale more black carbon than pedestrians

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Researchers devise protein 'switch' that instructs cancer cells to produce their own medication

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Scientists find a way to rapidly produce pure populations of oligodendrocyte progenitor cells

Patrys announced PAT-SM6 has efficacy against multiple myeloma in preclinical trials

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics